In recent years, the domestic in vitro diagnosis (IVD) industry has grown rapidly. According to the data released by Evaluate MedTech, from 2014 to 2017, the global market sales scale of IVD industry has increased year by year, from $49 billion 900 million in 2014 to $52 billion 600 million in 2017, with an annual composite growth rate of 1.8%; in 2024, the market sales scale is expected to reach $79 billion 600 million, from 2017 to 2024 The compound annual growth rate reached 6.1%. In this context, the increasing clinical needs and industry application standards also put forward new requirements for IVD products and technologies. After ten years of independent development of "Lica light-induced chemiluminescence technology", as a new chemiluminescent immunoassay method, Kemei diagnosis creatively adopts homogeneous reaction system and nano high-tech particles, providing a new solution for many clinical laboratories. According to the public data, in the field of chemiluminescence immunodiagnosis in China, good localization results have been achieved in the field of medium and low-end immunodiagnosis. However, in China's high-end chemiluminescence market, imported manufacturers still occupy more than 80% of the market share. Among them, Abbott, Roche, Beckman and Siemens account for about 70% of the market share. However, with the improvement of China's medical consumption level, the promotion of medical system reform, and the strong support of national industrial policies, we have been focusing on the development of in vitro detection reagents, and hope to cooperate with you.